



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : C07F 9/22, 9/24, C07H 19/10 C07H 19/20	A1	(11) International Publication Number: WO 88/ 02004 (43) International Publication Date: 24 March 1988 (24.03.88)
(21) International Application Number: PCT/US86/01970 (22) International Filing Date: 20 September 1986 (20.09.86) (71) Applicant: APPLIED BIOSYSTEMS, INC. [US/US]; 850 Lincoln Centre Drive, Foster City, CA 94404 (US). (72) Inventors: FUNG, Steven ; 765 San Antonio Road #8, Palo Alto, CA 94303 (US). WOO, Sam, Lee ; 450 Carlos Road, Redwood City, CA 94061 (US). SMITH, Lloyd, M. ; 612 Meridian Avenue, South Pasadena, CA 91030 (US). (74) Agents: SMITH, Joseph, H. et al.; Wiseman, Jones & Smith, 12 South First Street, San Jose, CA 95113 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: AMINO-DERIVATIZED PHOSPHITE AND PHOSPHATE LINKING AGENTS, PHOSPHORAMIDITE PRECURSORS, AND USEFUL CONJUGATES (57) Abstract The compounds include novel linking agents comprising 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes and their phosphoramidite precursors. The compounds of the invention further include conjugates of the above linking agents with oligonucleotides and polymer supports. The compounds of the present invention are useful for linking organic moieties, such as fluorescent or chromogenic dyes, to polymer supports and oligonucleotides, particularly single- and double-stranded DNA and RNA fragments.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

AMINO-DERIVATIZED PHOSPHITE AND PHOSPHATE LINKING
AGENTS, PHOSPHORAMIDITE PRECURSORS,
5 AND USEFUL CONJUGATES

Background

The invention relates generally to
10 organophosphorous compounds, and more particularly, to
organophosphorous compounds for synthesizing amino-
derivatized polymers, especially oligonucleotides.

Genes and gene control regions can now be
routinely characterized and studied at the molecular
15 level. This is possible because of several recent
advances in the technology associated with manipulating
and modifying deoxyribonucleic acid (DNA). Of
particular importance have been advances in DNA
sequencing, Maxam and Gilbert, "Sequencing End-Labeled
20 DNA with Base-Specific Chemical Cleavages," and Smith,
"DNA Sequence Analysis by Primed Synthesis," pgs. 499-
560 and 560-580, respectively, in Methods in
Enzymology, Grossman and Moldave, eds., Vol. 65
(Academic Press, New York, 1980); the isolation of a
25 large number of host restriction modification enzymes,
Roberts, "Dictionary of Restriction Endonucleases," in
Methods in Enzymology, Wu, ed., Vol. 68 (Academic
Press, New York, 1979); and the construction of vectors
for cloning and amplifying defined DNA sequences, e.g.
30 Bolivar and Backman, "Plasmids of Escherichia coli as
Cloning Vectors," in Methods in Enzymology, Wu, ed.,
Vol. 68 (Academic Press, New York, 1979).

Many of these new techniques require that DNA
fragments or oligonucleotides be labeled or attached to
35 polymer supports. DNA sequencing techniques and gene
probes, which can be used to help locate natural genes
of commercial or scientific importance, require the use

-2-

of labeled oligonucleotides. Until recently, all DNA sequencing techniques relied on radioactive labels for distinguishing oligonucleotide fragments separated by electrophoresis. Radioactive labels are highly sensitive, and can be incorporated without steric hinderance, or other chemical side effects. However, their use poses a laboratory health hazard, which requires that they receive special handling and disposal. Moreover, their use is not amenable for rapid automatic sequencing of oligonucleotides, as nucleoside-specific radioactive labels are not available for practical identification of different nucleotide bases, and radiation detection techniques such autoradiography and scintillation counting are too time consuming. As a consequence, other non-radioactive labeling techniques have been sought, such as fluorescent and colorimetric labeling, which depend on the ability to covalently link a fluorescent or chromogenic molecule to an oligonucleotide.

Chu et al, in "Derivatization of Unprotected Polynucleotides," Nucleic Acids Research, Vol.11, pgs. 6513-6529(1983), disclose a method for attaching amines to the terminal 5'-phosphates of oligonucleotides. One object of the method is to provide a means for attaching organic labeling molecules to oligonucleotides by way of an amine linkage. The method involves treating the oligonucleotides with a carbodiimide.

Chollet and Kawashima, in "Biotin-Labeled Synthetic Oligodeoxyribonucleotides: Chemical Synthesis and Uses as Hybridization Probes," Nucleic Acids Research, Vol.13, pgs. 1529-1541 (1985), disclose the use of the method of Chu et al to attach biotin to the 5'-phosphate of an oligonucleotide. The reported yields of 50-70% are below that needed for use in automatic synthesizers, and the carbodiimide can cause

unwanted modifications to oligonucleotide bases in the course of the reaction.

Smith et al, in "Synthesis of Oligonucleotides Containing an Aliphatic Amino Group at the 5' Terminus: 5 Synthesis of Fluorescent DNA Primers for Use in DNA Sequence Analysis," Nucleic Acids Research, Vol.13, pgs. 2399-2412 (1985), disclose a protected amino-derivatized nucleoside phosphoramidite for linking 10 fluorescent or colorimetric tags to oligonucleotide fragments. While the linker is highly useful for attaching base-specific labels to the 5' terminus of oligonucleotides, the protected-amine phosphoramidite is not readily purified.

Connolly and Rider, in "Chemical Synthesis of 15 Oligonucleotides Containing a Free Sulphydryl Group and Subsequent Attachment of Thiol Specific Probes," Nucleic Acids Research, Vol. 13, pgs. 4485-4502 (1985), disclose the synthesis of oligonucleotides having a trityl-protected sulphur attached via a two, three, or 20 six carbon chain to the 5' phosphate of the oligonucleotide.

Apart from linking labeling agents to oligonucleotides, there is great interest in immobilizing various molecules on polymer supports, 25 such as catalysts, enzymes, microorganisms, affinity reagents, immunoadsorbents, and the like, for both preparative and analytical uses, e.g. Schott, Affinity Chromatography (Marcel Dekker, Inc., New York,1984), and Mosbach, ed., Methods in Enzymology, Vol.44, 30 "Immobilized Enzymes," (Academic Press, New York, 1976). Of particular interest in this field are means for immobilizing molecules and cells by covalent bonds.


Summary of the Invention

35 The compounds of the invention include novel linking agents comprising 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes and their

phosphoramidite precursors. The compounds of the invention further include conjugates of the above mentioned linking agents with oligonucleotides, conjugates of the above mentioned linking agents with
5 polymer supports, and conjugates comprising dyes linked to oligonucleotides by the above mentioned linking agents. The present invention relates to compounds that are useful for linking organic moieties, such as
10 fluorescent and chromogenic dyes, to DNA fragments and oligonucleotides, particularly single-stranded DNA and RNA, and for linking DNA fragments, oligonucleotides, proteins, and the like to polymer supports. The
15 compounds and their conjugates are useful in automated and manual DNA and RNA synthesis and sequence analysis, construction of gene probes, affinity techniques, and the like. In particular, the cyclic embodiments of the
linking agents of the invention advantageously overcome deficiencies associated with currently available
20 linking methods by providing more readily purified linking agents.

Description of the Invention

The linking compounds of the present invention include 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes defined by the formula:
25



Formula I

wherein:

n is in the range of 2 to 4, preferably in the range of 2 to 3, and most preferably is equal to 2.

R₁ represents an amino protection group,
5 preferably either acid-labile or base-labile, e.g. as described by Greene, in Protective Groups in Organic Synthesis (John Wiley & Sons, New York, 1981), chapter 7, which chapter is incorporated by reference.
Preferably base-labile protection groups when taken
10 together with the nitrogen of the heterocycle or that of its precursor, are base-labile amide and carbamate protection groups, preferably trihaloacetyls, acetoacetyl, and fluorenylmethyl carbamates, particularly 9-fluorenylmethyl carbamate and 9-(2-
15 sulfo)-fluorenylmethyl carbamate, and most preferably trifluoroacetyl. Preferable acid-labile protection groups include trityls, and their lower (containing from 1-3 carbon atoms) alkoxy derivatives, particularly

20 R₂ and R₃ are chosen so that (1) the likelihood that they sterically hinder the cyclization of the compound of Formula I is minimized, (2) the ring electron density of the heterocycle of Formula I is reduced, because it is thought that this will enhance
25 the reactivity or the N-P bond in the compound of Formula I to hydroxyl groups, and (3) the molecular weight of the compound of Formula I is minimized to increase the likelihood that it can be purified by distillation. R₂ and R₃ taken separately each
30 represent hydrogen, lower alkyl, lower substituted alkyl, particularly halo-, cyano-, or nitro-substituted lower alkyl, lower acyl, cyano, halo, and nitro; more preferably R₂ and R₃ taken separately each represent hydrogen, lower alkyl, and lower haloalkyl;
35 and most preferably R₂ and R₃ represent hydrogens.

R₄ represents alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms. More

preferably, R_4 represents lower alkyl; electron-withdrawing beta-substituted ethyl, particularly beta-trihalomethyl-, beta-cyano-, beta-sulfo-, beta-nitro-substituted ethyl, or the like; electron-withdrawing substituted phenyl, particularly halo-, sulfo-, cyano-, or nitro-, substituted phenyl; or electron-withdrawing substituted phenylethyl. Most preferably, R_4 represents methyl, beta-cyanoethyl, or 4-nitrophenylethyl.


The term "lower alkyl" as used herein denotes straight-chain and branched-chain alkyl groups containing from 1-6 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, sec-butyl, neopentyl, tert-pentyl, and the like. "Lower substituted alkyl" denotes lower alkyl having electron-withdrawing substituents, such as halo, cyano, nitro, sulfo, or mono-, di-, or trihalomethyl, or the like. "Lower haloalkyl" denotes a lower alkyl with one or more halogen atom substituents, usually fluoro, chloro, bromo, or iodo. "Lower acyl" denotes an acyl containing from 1-7 carbon atoms wherein the non-double bonded carbons comprise a lower alkyl, possibly having halo-, cyano-, or nitro- substituents. "Electron-withdrawing" denotes the tendency of a substituent to attract valence electrons of the molecule of which it is apart, i.e. it is electronegative.

A special case of the above-described linking agent includes bicyclic compounds defined by the formula:

-7-

5

10


Formula II

15

wherein m is in the range of 1 to 3, and n , R_1 , and R_4 are as defined above. More preferably m is in the range of 1 to 2; and most preferably m is 1. The lower cycloalkyl attached to the oxazaphospha-heterocycle is thought to introduce ring strain into the heterocycle making the nitrogen-phosphorous bond more reactive.

The linking compounds of the invention also include the phosphoramidite precursors to the above 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes, the precursors being defined by the formula:

30



35

Formula III

-8-

wherein:

R_1 , R_2 , R_3 , and R_4 are as indicated above;


j is in the range of 2 to 10, more preferably in the range of 2 to 4, and most preferably j is in the range of 2 to 3 (it is believed that this latter range results in a precursor possessing the most favorable steric configuration for cyclization); and

R' and R'' taken separately each represent alkyl, aralkyl, cycloalkyl, and cycloalkylalkyl containing up to 10 carbon atoms. Preferably R' and R'' taken separately represent lower alkyl, and most preferably when the above phosphoramidites are used directly as linking agents, R' and R'' taken separately are sterically hindering lower alkyls which enhance the chemical stability of the phosphoramidites, and hence their shelf lives. Such sterically hindering lower alkyls include isopropyl, t-butyl, isobutyl, sec-butyl, neopentyl, tert-pentyl, isopentyl, sec-pentyl, and the like. Most preferably, when the above phosphoramidites are used as precursors to the above-described oxazaphospha-heterocycle, R' and R'' taken separately are isopropyl.

R' and R'' taken together form an alkylene chain containing up to 5 carbon atoms in the principal chain and a total of up to 10 carbon atoms with both terminal valence bonds of said chain being attached to the nitrogen atom to which R' and R'' are attached; or R' and R'' when taken together with the nitrogen atom to which they are attached form a saturated nitrogen heterocycle which may contain one or more additional heteroatoms from the group consisting of nitrogen, oxygen, and sulfur. More preferably, R' and R'' taken together and with the nitrogen to which they are attached represent pyrrolidino, morpholino, or piperidino. Most preferably, R' and R'' taken together and with the nitrogen to which they are attached represent morpholino.

The phosphoramidite precursors to the above-described 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes include substituted lower cycloalkanes defined by the formula:

5




15

Formula IV

wherein R_1 , R_4 , R' , and R'' are as indicated above, and t is in the range of 0 to 8, and s is in the range of 0 to 8, subject to the condition that $s+t$ is in the range of 1 to 8, more preferably t is in the range of 0 to 2, and s is in the range of 1 to 3, still more preferably t is 0 and s is in the range of 1 to 2, and most preferably t is 0 and s is 1.

25 Conjugates of the present invention include triester phosphite and triester and diester phosphate compounds of the formula:



15

Formula V

wherein:

i is 0 or 1 (where i=0 indicates phosphite, and i=1 indicates phosphate);

20 k equals 1 (where k=0 indicates diester, and k=1 indicates triester) whenever i equals 0, or k equals 0 or 1 whenever i equals 1;

j, R₁, R₂, R₃, and R₄ are as indicated above; and

W represents an oligonucleotide, a polymer support, or an oligonucleotide linked to a polymer support. Oligonucleotides include fragments of single-stranded and double-stranded RNA, and fragments of single- and double-stranded DNA. Preferably the linking agent is conjugated to the terminal 5' carbon of an oligonucleotide, the terminal 3' carbon of an oligonucleotide, or the terminal 2' carbon of RNA. More preferably, the linking agent is conjugated to the terminal 5' carbon of an oligonucleotide, and most preferably the linking agent is conjugated to the terminal 5' carbon of a fragment of single-stranded DNA.

35

Polymer supports may have a variety of forms and compositions. The polymer support can be derived from

naturally occurring materials, naturally occurring materials which are synthetically modified, and synthetic materials. Of particular interest are polysaccharides, particularly crosslinked

5 polysaccharides, such as agarose, which is available as Sepharose, dextran, available as Sephadex and Sephacyl, cellulose, starch and the like (Sepharose, Sephadex, and Sephacyl being trademarked products of Pharmacia Fine Chemicals). Other materials include

10 polyacrylamides, polystyrenes, polyvinyl alcohols, copolymers of hydroxyethyl methacrylate and methyl methacrylate, silicones, teflons glasses, cells, or the like. In addition to solid supports in the form of particles and the like, the polymer support may also be

15 in the form of liquid particles comprising a lipophilic or amphiphilic membrane, which serves to contain an internal fluid and define a space. Such particles include vesicles, cells, and liposomes. Preferably A' represents an insoluble polymer support having hydroxyl

20 functionalities. The linking agents of the invention are attached to polymer supports having hydroxyl functionalities by following the procedures generally described below for attaching the linking agents to oligonucleotides.


25 The bracket on the lefthand side of Formula V (enclosing H and R₁) indicates that this embodiment includes both the protected and deprotected forms of the compound.

Oligonucleotides are linked to polymer supports by

30 standard techniques of affinity chromatography or, for example, by linking means disclosed by Caruthers et al. in U.S. Patents 4,458,066 and 4,415,732, or the like.

The triester phosphite and triester and diester phosphate conjugates of the present invention further

35 include^c compounds of the formula:



10

Formula VI


15 wherein i, k, s, t, R₁, R₄, and W are as indicated above.

Generally the triester phosphate compounds of the invention are readily obtained from the above-defined phosphite conjugates by oxidation, e.g. with the use of I₂ in water, 2,6-lutidine and tetrahydrofuran. Oxidation is extremely rapid (1-2 minutes).

20 The diester phosphate conjugates of the invention are readily obtained from the above-defined triester phosphates by standard techniques, for example when R₄ is methyl, the diester phosphates are obtained from the triester phosphates by treatment with thiophenol/triethylamine for about 30 minutes. The general procedure for synthesizing the phosphoramidite precursors of Formulas III and IV comprises the following steps. Halo-substituted-N,N-di-substituted-O-substituted phosphine, defined by the formula:

30


5



10

wherein X is a halogen, usually chloro, and R', R'',
 and R₄ are as indicated above, is reacted with an
 15 amino-protected alcohol amine defined by the formula:

20



25

wherein R₁, R₂, and R₃ are as indicated above, in an
 aprotic solvent, such as dichloromethane, or the like,
 containing a non-nucleophilic base, for example a
 trialkylamine, such as N,N-diisopropylethyl amine, or
 30 the like, which absorbs the halogen acid released
 during the reaction. Preferably the reaction takes
 place under an inert atmosphere, such as argon. Acid
 conditions in the reaction mixture should be avoided as
 acid causes the amine of the phosphoramidite product to
 35 protonate, and thereby become reactive. The non-
 nucleophilic base reduces the likelihood of side

reactions between the base and activated phosphoramidites.

Whenever the alkyl moiety, i.e. $-(CR_2R_3)_n-$, of the amino-protected alcohol amine is cycloalkyl, e.g. as in
5 Formula IV, the amide or carbamate moiety of the alcohol amine is preferably in the cis configuration with the hydroxy; otherwise, formation of the oxazaphospha-heterocycle becomes unlikely, or even
10 impossible, because of the spacial separation of the two groups.

After reacting the above materials, the reaction mixture, hereinafter referred to as the first reaction mixture, is washed with a mildly basic solution to remove salts of the non-nucleophilic base. Finally,
15 the first reaction mixture is dried, e.g. with $MgSO_4$, Na_2SO_4 , or the like, to give the phosphoramidite precursor.

The heterocycles of Formulas I and II are obtained by heating the appropriate precursor represented by
20 Formulas III or IV, respectively, to form a second reaction mixture, and then separating the heterocycle from the mixture. The necessary amount of heating, i.e. temperature and duration, varies with different embodiments of the invention, preferably heating
25 includes raising the precursor to a temperature within the range of about 25 to 250 °C, more preferably from about 25 to 150 °C, and most preferably from about 25 to 100 °C. The choice of method of separation depends on the nature of the substituent groups, R_1 , R_2 , R_3 ,
30 and R_4 . For example, as a rough approximation when the aggregate molecular weight of the substituents is sufficiently low, the steps of heating and separating can be accomplished by distilling. Other methods of separation include crystallization and chromatography.
35 Preferably conjugates of oligonucleotides and linking agents of the invention are formed by attaching the linking agent to oligonucleotides synthesized by the

solid phase synthetic methods developed by Caruthers and his coworkers, e.g. Caruthers et al., pgs. 1-17, in Genetic Engineering, Vol. 4, Setlow and Hollaender, Eds. (Plenum Press, New York, 1982), and Caruthers et al., U.S. Patent 4,458,066. Attachment of the linking agent occurs as the final step in the synthetic process; that is, the linking agent is attached to the oligonucleotide as if it were a nucleotide subunit in the Caruthers et al. method.

The following examples serve to illustrate the present invention. The concentrations of reagents, temperatures, and values of other variable parameters are only to exemplify the application of the present invention and are not to be considered as limitations thereof.

EXAMPLE I. Synthesis of the phosphoramidite precursor of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane

Chloro-N,N-diisopropylaminomethoxy phosphine (5.0 ml, available from Aldrich Chemical Co., Milwaukee, WI) was added dropwise at 0 °C to a stirred solution of N-(2-hydroxyethyl)-2,2,2-trifluoroacetamide (3.9 g) and diisopropylethylamine (5.0 ml) in dichloromethane (about 40 ml) under argon. (N-(2-hydroxyethyl)-2,2,2-trifluoroacetamide is synthesized following the procedures disclosed by Lazarus and Benkovic in J. Am. Chem. Soc., Vol. 101, pgs. 4300-4312 (1979): Ethyl trifluoroacetate (56.8g, 0.4 mol) in 50 mL of chloroform is added dropwise to a stirred solution of 24.4 g (0.4 mol) of ethanolamine in 50 mL of chloroform. The solution is stirred at room temperature for 5 h, rotary evaporated to remove the solvent, and distilled at 115 °C (4.3 Torr) to give 58.5 g of oil that crystallized upon scratching.) After stirring at room temperature for 0.5 hours the reaction mixture was

washed twice with 0.2 M potassium carbonate solution and once with brine, dried (MgSO_4), and concentrated under reduced pressure to give N-(2-(N',N'-

diisopropylaminomethoxyphosphinyloxy)ethyl)-2,2,2-trifluoroacetamide as a colorless liquid (7.77 g).

^1H -NMR (CD_2Cl_2): δ 3.6 (6H, m), 3.4 (3H, d, $J=12$), 1.2 (12H, d, $J=6.5$)

^{31}P -NMR (CD_2Cl_2 , ^1H decoupled): δ 149(s)

10

EXAMPLE II. Synthesis of the phosphoramidite precursor of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclohexane

Chloro-N,N-diisopropylaminomethoxy phosphine (3.7 ml) was added dropwise at 0 °C to a stirred solution of N-(3-hydroxypropyl)-2,2,2-trifluoroacetamide (2.9 g, synthesized from 3-amino-1-propanol and ethyltrifluoroacetate in a manner similar to that disclosed by Lazarus and Benkovic, J. Amer. Chem. Soc., Vol.101, pgs. 4300-4312 (1979)) and diisopropylethylamine (3.7 ml) in dichloromethane (about 20 ml) under argon. After stirring at room temperature for 3 hours, the reaction mixture was poured into hexane (100 ml) and stirred. The mixture was allowed to settle and the supernatant was separated and concentrated under reduced pressure to give N-(3-(N',N'-diisopropylaminomethoxyphosphinyloxy)propyl)-2,2,2-trifluoroacetamide as a colorless liquid (5.2 g).

30 ^{31}P -NMR (CH_2Cl_2 , ^1H decoupled): δ 149 (s)

EXAMPLE III. Synthesis of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane

35 N-(2-(N',N'-diisopropylaminomethoxyphosphinyloxy)ethyl)-2,2,2-trifluoroacetamide (7.7 g) was distilled (58-59 °C at 0.8 Torr) to quantitatively yield 2-

methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane as a colorless liquid.

IR (film): 1705, 1420, 1230, 1200, 1160, 1020, 965 cm^{-1}

5 ^1H -NMR (CD_2Cl_2): δ 4.45 (2H, m), 3.65 (2H, m),
3.60 (3H, d, $J=12$)

^{31}P -NMR (CD_2Cl_2 , ^1H decoupled): δ 132(s), 125 (q, $J=61$)

MS: m/e 217 (M^+), 197, 148, 136, 123, 120, 109, 92,
79, 70(100), 69, 62

10

EXAMPLE IV. Attaching 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane to the 5' terminus of an oligonucleotide

15 Attachment of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane to a 5' hydroxyl of an oligonucleotide was performed on an Applied Biosystems 380A DNA synthesizer (Applied Biosystems, Foster City, CA), or comparable instrument. Caruthers et al, U.S. Patent
20 4,458,066; Caruthers et al, U.S. Patent 4,415,732; and Caruthers et al, "New Methods for Synthesizing Deoxy-oligonucleotides," in Genetic Engineering, Vol. 4, pgs. 1-17 (Plenum Press, New York, 1982) provide detailed descriptions of the chemistry used by the Applied
25 Biosystems 380A DNA synthesizer. Accordingly, these references are incorporated by reference for those descriptions. 2-Methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane was used as a 0.2 M acetonitrile solution in combination with 0.5 M tetra-
30 zole/acetonitrile solution to form an activated reagent in the synthesis cycle. The normal synthesizer cycle was modified only during the addition of the activated reagent in the following manner. The activated reagent was added twice with 1 hour wait times after each
35 addition. The coupling yields were about 95%. Normal deprotection with thiophenol/triethylamine and then ammonium hydroxide gave a 5'-aminoethylphosphate

oligonucleotide. Similar yields were obtained when the activated reagent comprised an acetonitrile solution containing 0.2 M 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane and 0.1 M 4-dimethyl-aminopyridine. In this case the modified activator reagent was added once, and allowed to react for about 15 minutes.

EXAMPLE V. Attaching 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane to the 3' terminus of an oligonucleotide

Attachment is accomplished in substantially the same manner as described in Example IV, except the oligonucleotide is synthesized in the 3' direction in accordance with the procedure generally described in Caruthers et al, U.S. Patent 4,458,066. (Roughly the difference is that the oligonucleotide is synthesized from 5' N,N-diisopropylaminophosphoramidites of 3'-protected nucleosides instead of 3' N,N-diisopropylaminophosphoramidites of 5'-protected nucleosides. Alternatively, the oligonucleotide is synthesized in the 3' direction using the phosphotriester method of Khorana and Itakura (i.e., Khorana, Science, Vol. 203, pgs. 614-625 (1979); Itakura et al. J. Biol. Chem., Vol. 250, pgs. 4592-4600, both of these references being incorporated by reference), or its modification by others, for example Letsinger and Mahaderan, J. Am. Chem. Soc., Vol. 187, pgs. 3526- (1965). In any case the linking agent is attached as a final addition in place of a nucleotide.


EXAMPLE VI. Attaching Fluorescein isothiocyanate (FITC) to a 5' aminoethylphosphate oligonucleotide

A dimethylformamide solution of fluorescein-6-isothiocyanate (25 microliters at a concentration of 10

mg/ml, e.g. available from Molecular Probes, Inc.,
Junction City, OR) was added to a solution of 5'-
aminoethylphosphate TCCCAGTCACGACGTT (0.020 micromole,
unpurified material being made on an Applied Biosystems
5 380A DNA synthesizer; here T=thymidine, C=cytidine,
G=guanosine, and A=adenosine) in water (200
microliters) and 1 M $\text{NaHCO}_3/\text{Na}_2\text{CO}_3$ buffer, pH 9.0 (25
microliters). The resulting solution was stored in the
dark at room temperature for at least 6 hours. To
10 remove the unconjugated dye, the reaction mixture was
passed through an equilibrated 10 ml Sephadex
(trademark of Pharmacia Fine Chemicals) G-25 (medium)
column with water. The band of colored material in the
excluded volume was collected. The crude 5'-
15 fluorescein aminoethylphosphate oligonucleotide was
purified by HPLC (e.g. Perkin-Elmer Series 4, or
comparable instrument) on a Vydac C18 column (No.
218TP54), or the like, in a linear gradient of 10-20%
acetonitrile/0.1 M triethylammonium acetate, pH 7.0.

We claim:

- 5 1. A compound of the formula:



wherein:

- n is in the range of 2 to 4;
R₁ is an amino protection group;
R₂ and R₃ taken separately each represent
25 hydrogen, lower alkyl, lower substituted alkyl, lower
cycloalkyl, lower acyl, cyano, halo, or nitro; and
R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl
containing up to 10 carbon atoms.
- 30 2. A compound according to Claim 1 wherein n is in
the range of 2 to 3.
3. A compound according to Claim 2 wherein R₁ taken
together with the nitrogen to which it is attached
35 represents a base-labile amide or carbamate protection
group, and R₄ represents lower alkyl, electron-
withdrawing beta-substituted ethyl, electron-

withdrawing substituted phenylethyl, or electron-withdrawing substituted phenyl.

4. A compound according to Claim 3 wherein R₄ represents lower alkyl; beta-trihalomethyl-, beta-nitro-, beta-sulfo-, or beta-cyano- substituted ethyl; halo-, nitro-, sulfo-, or cyano- substituted phenyl; or halo-, nitro-, sulfo-, or cyano- substituted phenylethyl.

10

5. A compound according to Claim 4 wherein R₄ is methyl, beta-cyanoethyl, or 4-nitrophenylethyl.

6. A compound according to Claim 5 wherein R₄ is methyl, or beta-cyanoethyl.

15

7. A compound according to Claim 3 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

20

8. A compound according to Claim 7 wherein R₄ is lower alkyl; beta-trihalomethyl-, beta-nitro-, beta-cyano-, or beta-sulfo- substituted ethyl; halo-, nitro-, cyano-, or sulfo- substituted phenyl; or halo-, nitro-, cyano-, or sulfo- substituted phenylethyl.

25

9. A compound according to Claim 8 wherein R₄ is methyl, beta-cyanoethyl, or 4-nitrophenylethyl.

10. A compound according to Claim 9 wherein R₄ is methyl, or beta-cyanoethyl.


30

11. A compound according to Claim 7 wherein R₁ is trifluoroacetyl, acetoacetyl, 9-(2-sulfo)-fluorenylmethyl carbamate, or 9-fluorenylmethyl carbamate.

35

12. A compound according to Claim 11 wherein R_4 is methyl, beta-cyanoethyl, or 4-nitrophenylethyl, and wherein R_2 and R_3 are hydrogens.
- 5 13. A compound according to Claim 12 wherein R_1 is trifluoroacetyl or acetoacetyl, and wherein R_4 is methyl or beta-cyanoethyl.
- 10 14. A compound according to Claim 2 wherein R_1 is an acid-labile amino protection group.
- 15 15. A compound according to Claim 14 wherein R_4 is lower alkyl; beta-trihalomethyl-, beta-nitro-, beta-sulfo-, or beta-cyano-substituted ethyl; halo-, nitro-, cyano-, or sulfo-substituted phenyl; or halo-, nitro-, cyano-, or sulfo-substituted phenylethyl.
- 20 16. A compound according to Claim 15 wherein R_1 is trityl or lower alkoxy-substituted trityl.
17. A compound according to Claim 16 wherein R_1 is 4-monomethoxytrityl or 4,4'-dimethoxytrityl.
- 25 18. A compound according to Claim 17 wherein R_4 is methyl or beta-cyanoethyl.
19. 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane.
- 30 20. 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclohexane.

21. A compound of the formula:



wherein:

m is in the range of 1 to 3;

n is in the range of 2 to 3;

R₁ is an amino protection group; and

20 R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms.

22. A compound according to Claim 21 wherein:

m is in the range of 1 to 2;

25 n is 2;

R₁ taken together with the nitrogen atom to which it is attached represents a base-labile amide or carbamate protection group; and

30 R₄ represents lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-nitro-, or beta-sulfo- substituted ethyl; halo-, nitro-, cyano-, or sulfo- substituted phenyl; or halo-, nitro-, cyano-, or sulfo- substituted phenylethyl.

35 23. A compound according to Claim 22 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl

carbamate, and R_4 is methyl, beta-cyanoethyl, or 4-nitrophenylethyl.


24. A compound according to Claim 23 wherein R_1 is trifluoroacetyl, or acetoacetyl, and R_4 is methyl or beta-cyanoethyl.

25. A compound according to Claim 21 wherein:
 m is in the range of 1 to 2;
 n is 2;
 R_1 is an acid-labile amino protection group; and
 R_4 is lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-nitro-, or beta-sulfo- substituted ethyl; halo-, nitro-, cyano-, or sulfo- substituted phenyl; or halo-, nitro-, cyano-, or sulfo- substituted phenylethyl.

26. A compound according to Claim 25 wherein R_1 is trityl or lower alkoxy-substituted trityl, and R_4 is methyl, beta-cyanoethyl, or 4-nitrophenylethyl.

27. A compound according to Claim 26 wherein R_1 is 4,4'-dimethoxytrityl or 4-monomethoxytrityl, and R_4 is methyl or beta-cyanoethyl.

28. A compound of the formula:



wherein:

j is in the range of 2 to 10;

R₁ is an amino protection group;

R₂ and R₃ taken separately each represent
5 hydrogen, lower alkyl, lower substituted alkyl, lower
cycloalkyl, lower acyl, cyano, halo, or nitro;

R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl
containing up to 10 carbon atoms;

R' and R'' taken separately each represent alkyl,
10 aryl, aralkyl, cycloalkyl, or cycloalkylalkyl
containing up to 10 carbon atoms; and

R' and R'' taken together form an alkylene chain
containing up to 5 carbon atoms in the principal chain
and a total of up to 10 carbon atoms with both terminal
15 valence bonds of said chain being attached to the
nitrogen atom to which R' and R'' are attached; or R'
and R'' when taken together with the nitrogen atom to
which they are attached form a saturated nitrogen
heterocycle.

20

29. A compound according to Claim 28 wherein j is in
the range of 2 to 4.

25

30. A compound according to Claim 29 wherein j is in
the range of 2 to 3.

30

31. A compound according to Claim 30 wherein R₁ taken
together with the nitrogen to which it is attached
represents a base-labile amide or carbamate protection
group, and R₄ represents lower alkyl, electron-
withdrawing beta-substituted ethyl, electron-
withdrawing substituted phenyl, or electron-withdrawing
substituted phenylethyl.

35

32. A compound according to Claim 31 wherein R₄ is
lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-
nitro-, or beta-sulfo- substituted ethyl; halo-, cyano-,

nitro-, or sulfo- substituted phenyl; or halo-,
cyano-, nitro-, or sulfo- substituted phenylethyl.

5 33. A compound according to Claim 32 wherein R_4 is
methyl, 4-nitrophenylethyl, or beta-cyanoethyl.

34. A compound according to Claim 31 wherein R_1 is
trihaloacetyl, acetoacetyl, or fluorenylmethyl
carbamate.

10

35. A compound according to Claim 34 wherein R_4 is
lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-
nitro-, or beta-sulfo- substituted ethyl; halo-, cyano-,
nitro-, or sulfo- substituted phenyl; or halo-,
15 cyano-, nitro-, or sulfo- substituted phenylethyl.

36. A compound according to Claim 35 wherein R_4 is
methyl, 4-nitrophenylethyl, or beta-cyanoethyl.

20 37. A compound according to Claim 36 wherein R_1 is
trifluoroacetyl, acetoacetyl, 9-(2-sulfo)-
fluorenylmethyl carbamate, or 9-fluorenylmethyl
carbamate.

25 38. A compound according to Claim 37 wherein R' and
 R'' taken separately are sterically hindering lower
alkyls, and R' and R'' taken together with the nitrogen
atom to which they are attached is morpholino,
pyrrolidino, or piperidino.

30

39. A compound according to Claim 38 wherein R' and
 R'' taken separately are isopropyls, and R' and R''
taken together is morpholino.

35 40. A compound according to Claim 39 wherein R_2 and R_3
are hydrogens.

41. A compound according to Claim 30 wherein R_1 is an acid-labile amino protection group.

42. A compound according to Claim 41 wherein:

5 R_1 is trityl or lower alkoxy-substituted trityl;


R_4 is lower alkyl; beta-cyano-, beta-trihalomethyl-, beta-nitro-, or beta-sulfo-substituted ethyl; halo-, cyano-, nitro-, or sulfo-substituted phenyl; or halo-, cyano-, nitro-, or sulfo-substituted phenylethyl;

10 R' and R'' taken separately are sterically hindering lower alkyls; and

R' and R'' taken together with the nitrogen atom to which they are attached is morpholino, pyrrolidino, or piperidino.

43. A compound according to Claim 42 wherein R_1 is 4-monomethoxytrityl or 4,4'-dimethoxytrityl.

20 44. A cycloalkane of the formula:



the cycloalkane having a protected amino substituent and a phosphoramidite substituent wherein:

35 s is in the range of 0 to 8, t is in the range of 0 to 8, and $s+t$ is in the range of 1 to 8;

R_1 is an amino protection group;

R₄ is alkyl, alkenyl, aralkyl, or cycloalkyl containing up to 10 carbon atoms;

R' and R'' taken separately are sterically hindering lower alkyls; and

5 R' and R'' taken together with the nitrogen atom to which they are attached is morpholino, pyrrolidino, or piperidino.

10 45. A compound according to Claim 44 wherein s is in the range of 1 to 3, t is in the range of 0 to 2, and the protected amine and phosphoramidite substituents to the cycloalkane defined by said formula are in cis configuration.

15 46. A compound according to Claim 45 wherein R₁ taken together with the nitrogen atom to which it is attached represents a base-labile amide or carbamate protection group, and R₄ represents lower alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing
20 substituted phenylethyl.

25 47. A compound according to Claim 46 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

48. A compound according to Claim 47 wherein:
t is 0;
s is in the range of 1 to 2;
30 R₁ is trifluoroacetyl or acetoacetyl;
R₄ is methyl, 4-nitrophenylethyl, or beta-cyanoethyl;
R' and R'' taken separately are isopropyl; and
R' and R'' taken together with the nitrogen atom
35 to which they are attached is morpholino.

49. A compound according to Claim 45 wherein R_1 is an acid-labile amino protection group.

50. A compound according to Claim 49 wherein:

5 R_4 is lower alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing substituted phenylethyl;


10 R' and R'' taken separately represent sterically hindering lower alkyls; and

R' and R'' taken together with the the nitrogen atom to which they are attached represents morpholino, pyrrolidino, or piperidino.

15 51. A compound according to Claim 50 wherein t is 0, s is in the range of 1 to 2, and R_1 is trityl or lower alkoxy-substituted trityl.

20 52. A compound according to Claim 51 wherein R_1 is 4-monomethoxytrityl or 4,4'-dimethoxytrityl.

53. A compound of the formula:



35 wherein:

i is 0 or 1;

j is in the range of 2 to 10;

k is 1 whenever i is 0, or k is 0 or 1 whenever i is 1;

R₁ is an amino protection group;

5 R₂ and R₃ taken separately each represent hydrogen, lower alkyl, lower substituted alkyl, lower cycloalkyl, lower acyl, cyano, halo, or nitro;

R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms; and

10 W represents an oligonucleotide, a polymer support, or an oligonucleotide linked to a polymer support.

54. A compound according to Claim 53 wherein R₂ and R₃ are hydrogens, and R₄ is lower alkyl, electron-
15 withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing substituted phenylethyl.

55. A compound according to Claim 54 wherein j is in
20 the range of 2 to 4.

56. A compound according to Claim 55 wherein W is an oligonucleotide.

25 57. A compound according to Claim 56 wherein R₁ taken together with the nitrogen atom to which it is attached is a base-labile carbamate or amide protection group.

58. A compound according to Claim 57 wherein R₁ is
30 trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

59. A compound according to Claim 56 wherein R₁ is an acid-labile amino protection group.

35

60. A compound according to Claim 59 wherein R₁ is trityl or lower alkoxy-substituted trityl.

-31-


61. A compound according to Claim 55 wherein W is a polymer support.

62. A compound according to Claim 61 wherein said polymer support is a cross-linked polysaccharide.

63. A compound according to Claim 62 wherein said cross-linked polysaccharide is selected from the group consisting of dextran, cellulose, and agarose.

10

64. A compound of the formula:



wherein:

25 R_1 is an amino protection group;

s is in the range of 0 to 8, t is in the range of 0 to 8, and $s+t$ is in the range of 1 to 8;

30 R_4 represents lower alkyl; electron-withdrawing beta-substituted ethyl; electron-withdrawing substituted phenyl; or electron-withdrawing substituted phenylethyl;

i is 0 or 1;

k is 1 whenever i is 0, or k is 0 or 1 whenever i is 1; and

35 W is an oligonucleotide, a polymer support, or an oligonucleotide linked to a polymer support.

65. A compound according to Claim 64 wherein t is in the range of 0 to 2, s is in the range of 1 to 3.
- 5 66. A compound according to Claim 65 wherein W is an oligonucleotide.
- 10 67. A compound according to Claim 66 wherein R₁ taken together with the nitrogen atom to which it is attached is a base-labile amide or carbamate protection group.
- 15 68. A compound according to Claim 67 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.
- 20 69. A compound according to Claim 68 wherein t is 0, s is in the range of 1 to 2.
70. A compound according to Claim 66 wherein t is in the range of 0 to 2, s is in the range of 1 to 3, and R₁ is an acid-labile amino protection group.
- 25 71. A compound according to Claim 70 wherein R₁ is trityl or lower alkoxy-substituted trityl.
72. A compound according to Claim 65 wherein W is a polymer support.
- 30 73. A compound according to Claim 72 wherein said polymer support is a cross-linked polysaccharide.
74. A method of synthesizing 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkanes, the method comprising the steps of:
- 35 heating a phosphoramidite precursor to form a reaction mixture containing a 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane; and

separating the 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane from the reaction mixture.

75. The method according to Claim 74 further including
5 the steps of:

reacting a halo-substituted-N,N-di-substituted-lower alkoxy phosphine with an amino-protected alcohol amine in an aprotic solvent to form a first reaction mixture containing said phosphoramidite precursor; and
10 separating said phosphoramidite precursor from the first reaction mixture.

76. The method according to Claim 75 wherein said step of heating includes heating to a temperature in the
15 range of about 25-250 °C.

77. The method according to Claim 76 wherein said step of heating includes heating to a temperature in the range of about 25-150 °C.
20

78. The method according to Claim 77 wherein said step of heating includes heating to a temperature in the range of about 50-100 °C.

79. The method according to Claim 75 wherein said step of separating said 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane includes distilling.
25

80. The method according to Claim 79 wherein said 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane
30 is 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane or 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclohexane.

81. A method of labeling an oligonucleotide,
35 comprising the steps of:

reacting a 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane linking agent with an unprotected hydroxyl of the oligonucleotide to form a linker-oligonucleotide conjugate, the 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane linking agent having a protected amine;

deprotecting the protected amine; and
reacting a label with the deprotected amine.

82. The method according to Claim 81 further including the step of synthesizing said oligonucleotide by a solid phase synthesis procedure, and wherein said step of reacting a 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane is accomplished as a final addition step in said solid phase synthesis procedure.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US86/01970

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³ According to International Patent Classification (IPC) or to both National Classification and IPC INT. CL. (4): C07F 9/22; C07F 9/24; See Attachment U.S. CL. 536/27; 536/28; 536/29; 544/157; See Attachment																							
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁴</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; text-align: left; border-bottom: 1px solid black;">Classification System</th> <th style="text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">U.S.</td> <td style="padding: 5px;">536/27; 536/28; 536/29; 544/157; 546/21; 548/412; 558/81; 558/170; 558/190</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵</div>			Classification System	Classification Symbols	U.S.	536/27; 536/28; 536/29; 544/157; 546/21; 548/412; 558/81; 558/170; 558/190																	
Classification System	Classification Symbols																						
U.S.	536/27; 536/28; 536/29; 544/157; 546/21; 548/412; 558/81; 558/170; 558/190																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴ <table style="width: 100%; border-collapse: collapse; border-top: 1px solid black; border-bottom: 1px solid black;"> <tr> <th style="width: 10%; text-align: left; border-bottom: 1px solid black;">Category *</th> <th style="text-align: left; border-bottom: 1px solid black;">Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷</th> <th style="text-align: left; border-bottom: 1px solid black;">Relevant to Claim No. ¹⁸</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US,A, 3,172,903, REETZ, published 9 March 1965 (Columns 1-2)</td> <td style="vertical-align: top; padding: 5px;">1-20 and 74-80</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US,A, 3,652,742, SIRRENBURG, published 28 March 1972 (Columns 1-5, 21-22)</td> <td style="vertical-align: top; padding: 5px;">28-52</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US,A 4,324,744, LECHTKEN published 13 April 1982 (Columns 1-2)</td> <td style="vertical-align: top; padding: 5px;">28-52</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US,A, 4,458,066, CARUTHERS published 3 July 1984 (Columns 5-8)</td> <td style="vertical-align: top; padding: 5px;">53-73 81-82</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US,A, 4,507,433, MILLER, published 26 March 1985 (Columbus 2-18)</td> <td style="vertical-align: top; padding: 5px;">53-73 and 81-82</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US,A, 4,605,735, MIYOSHI, published 12 August 1986 (Columns 2-14)</td> <td style="vertical-align: top; padding: 5px;">53-73 and 81-82</td> </tr> </table>			Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸	A	US,A, 3,172,903, REETZ, published 9 March 1965 (Columns 1-2)	1-20 and 74-80	A	US,A, 3,652,742, SIRRENBURG, published 28 March 1972 (Columns 1-5, 21-22)	28-52	A	US,A 4,324,744, LECHTKEN published 13 April 1982 (Columns 1-2)	28-52	A	US,A, 4,458,066, CARUTHERS published 3 July 1984 (Columns 5-8)	53-73 81-82	A	US,A, 4,507,433, MILLER, published 26 March 1985 (Columbus 2-18)	53-73 and 81-82	A	US,A, 4,605,735, MIYOSHI, published 12 August 1986 (Columns 2-14)	53-73 and 81-82
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸																					
A	US,A, 3,172,903, REETZ, published 9 March 1965 (Columns 1-2)	1-20 and 74-80																					
A	US,A, 3,652,742, SIRRENBURG, published 28 March 1972 (Columns 1-5, 21-22)	28-52																					
A	US,A 4,324,744, LECHTKEN published 13 April 1982 (Columns 1-2)	28-52																					
A	US,A, 4,458,066, CARUTHERS published 3 July 1984 (Columns 5-8)	53-73 81-82																					
A	US,A, 4,507,433, MILLER, published 26 March 1985 (Columbus 2-18)	53-73 and 81-82																					
A	US,A, 4,605,735, MIYOSHI, published 12 August 1986 (Columns 2-14)	53-73 and 81-82																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																							
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse; border-top: 1px solid black; border-bottom: 1px solid black;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of the Actual Completion of the International Search ² <div style="text-align: center; font-size: 1.2em;">09 December 1986</div> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of Mailing of this International Search Report ³ <div style="text-align: center; font-size: 1.2em;">15 DEC 1986</div> </td> </tr> <tr> <td style="vertical-align: top; padding: 5px;"> International Searching Authority ¹ <div style="text-align: center; font-size: 1.2em;">ISA/US</div> </td> <td style="vertical-align: top; padding: 5px;"> Signature of Authorized Officer ²⁰ <div style="text-align: center;"> Johnnie R. Brown </div> </td> </tr> </table>			Date of the Actual Completion of the International Search ² <div style="text-align: center; font-size: 1.2em;">09 December 1986</div>	Date of Mailing of this International Search Report ³ <div style="text-align: center; font-size: 1.2em;">15 DEC 1986</div>	International Searching Authority ¹ <div style="text-align: center; font-size: 1.2em;">ISA/US</div>	Signature of Authorized Officer ²⁰ <div style="text-align: center;"> Johnnie R. Brown </div>																	
Date of the Actual Completion of the International Search ² <div style="text-align: center; font-size: 1.2em;">09 December 1986</div>	Date of Mailing of this International Search Report ³ <div style="text-align: center; font-size: 1.2em;">15 DEC 1986</div>																						
International Searching Authority ¹ <div style="text-align: center; font-size: 1.2em;">ISA/US</div>	Signature of Authorized Officer ²⁰ <div style="text-align: center;"> Johnnie R. Brown </div>																						

Attachment

I. Classification of Subject Matter

INT. CL(4): C07H 19/10; C07H 19/20

U.S. CL : 546/21; 548/412; 558/81; 558/170; 558/190

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹⁰

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ¹¹

This International Searching Authority found multiple inventions in this international application as follows:

See Attachment Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. Telephone Practice

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Attachment to form PCT/ISA/210
Part VI

- I. Claims 1-20 and 74-80 are drawn to 1,3,2-oxazaphosphacyclo-alkane compounds and a process for preparing the oxazaphospha-cycloalkane compounds, classified in Class 558, subclass 81.
- II. Claims 21-27, are drawn to 1,3,2-oxazaphosphabicycloalkane compounds, classified in Class 558, subclass 81.
- III. Claims 28-43 are directed to phosphoramidite compounds, classified in Classes 544; 546 and 548, subclasses 157,21 and 412, respectively.
- IV. Claims 44-52 are directed to phosphoramidite cycloalkane containing compounds, classified in Classes 544, 546 and 548, subclasses 157, 21 and 412, respectively.
- V. Claims 53-73 and 81-82 are drawn to oligonucleotide containing compounds and a process for preparing same, classified in Class 536, subclasses 27,28 and 29+.

Attachment to Form PCT/ISA 210
Part VI.1

Telephone Approval:

\$560.00 payment approved by Mr. Joseph H. Smith on 1 December 1986 for Groups I, II, III, IV and V; Charge to Deposit Account No. 10-1218.

Reasons for holding lack of unity of invention:

The invention as defined by Group I (claims 1-20 and 74-80) is drawn to Oxazaphosphacycloalkane compounds and a process for preparing the compounds which compounds are mutually exclusive and materially different from: the bicyclopheosphorus compounds defined by Group II (claims 21-27), the phosphoramidite compounds defined by Group III (claims 28-43), the cycloalkane phosphoramidite compounds defined by Group IV (claims 44-52) or the oligonucleotide compounds and the process for preparing the oligonucleotide compounds defined by Group V (claims 53-73 and 81-82).

The search burden involved for each additional invention is undue, not only insofar as the additional parent search indicated by the separate classifications, but also insofar as considerable additional literature searches covering the entire classes noted above.

Time Limit For Filing A Protest

Applicant is hereby given 15 days from the mailing date of this Search Report in which to file a protest of the holding of lack of unity of invention. In accordance with PCT Rule 40.2 applicant may protest the holding of lack of unity only with respect to the group(s) paid for.